2120 (2120) Fair Value & Analysis

Healthcare · Market cap HK$541M

2 2120 2120 · HK

PriceHK$7.67

Fair ValueHK$15.14

Upside+97.4%

Quality53/100

Watch 2120 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$13.55 – HK$18.93

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −18.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$7.67 – HK$12.08 · fair‑value band HK$13.55 – HK$18.93 · the HK$7.67 price screens below the HK$15.14 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2120 (2120) currently trades at HK$7.67, while our model-based Fair Value estimate is HK$15.14 — implying the stock looks roughly 97.4% undervalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 2120 generated revenue of HK$1.6B at a net margin of 3.4%. Revenue grew 6.8% year over year. It earns a return on equity of 2.8%. Net debt stands at HK$880M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.6B

Revenue growth (YoY) +6.8%

Net margin 3.4%

Return on equity 2.8%

Free cash flow HK$244M FY2025

P/E ratio 8.7

More key figures

Operating margin 10.4%

EPS (TTM) HK$0.5000

Dividend yield 6.5%

EPS growth (YoY) +26.6%

Net debt HK$880M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2120 reported revenue of HK$1.6B in FY2025 versus HK$1.3B in FY2021, a compound +5.7%/yr. Reported net income was HK$54.4M in FY2025, compounding +5.4%/yr from FY2021.

Revenue +5.7%/yr

FY21 HK$1.3B

FY22 HK$1.5B

FY23 HK$1.6B

FY24 HK$1.7B

FY25 HK$1.6B

Net income +5.4%/yr

FY21 HK$44.0M

FY22 −HK$24.2M

FY23 HK$85.9M

FY24 HK$65.6M

FY25 HK$54.4M

Is 2120 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$97.60	R$115.75	+19%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2120 (2120) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$15.14 versus a price of HK$7.67 — about +97% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2120?

Our model-based fair value for 2120 is HK$15.14 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.67.

What is the quality score of 2120?

2120 has a Quality Score of 53/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2120 (2120)?

2120 reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2120?

The net profit margin of 2120 is about 3.4%, meaning it keeps roughly 3.4% of revenue as net income. Based on the latest reported figures.

Does 2120 pay a dividend?

2120 currently shows a dividend yield of about 6.50% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.